June 25, 2024 08:07 AM EDT

AstraZeneca’s Imfinzi aces Phase 3 test in bladder cancer, fails another in lung cancer

Ayisha Sharma

News Reporter

You win some, you lose some: AstraZeneca’s blockbuster cancer medicine Imfinzi has succeeded in a late-stage bladder cancer trial, but disappointed in a separate Phase …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AstraZeneca’s Imfinzi aces Phase 3 test in bladder cancer, fails another in lung cancer

Ayisha Sharma

News Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

The Endpoints 11 winners: Big bets on AI, new frontiers in editing, a neuro renaissance and Chinese chemistry

Novo Nordisk to decrease some insulin pen manufacturing, transition supply

Exclusive: J&J folds cardiovascular and metabolic drug unit

FDA approves Dupixent in COPD, opening ‘next chapter’ for Sanofi and Regeneron’s bestseller

FDA approves Bristol Myers and Karuna's schizophrenia drug, in milestone for psychiatry

PDCs vs. ADCs: A New Frontier in Targeted Cancer Therapies and the Potential for Development Partnerships

As­traZeneca’s Imfinzi aces Phase 3 test in blad­der can­cer, fails an­oth­er in lung can­cer

News Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

AstraZeneca’s Imfinzi aces Phase 3 test in bladder cancer, fails another in lung cancer